Characterising burden of treatment in cystic fibrosis to identify priority areas for clinical trials

Gwyneth Davies[1][*][#], Nicola J Rowbotham[2][*], Sherie Smith[2][*], Zoe C Elliot[3], Katie Gathercole[4,5], Oli Rayner[6], Paul A Leighton[7], Sophie Herbert S[2], Alistair JA Duff[8], Suja Chandran S[9], Tracey Daniels[10], Edward F Nash[11], Alan R Smyth[2].

*joint first authors. #author for correspondence (Email: gwyneth.davies@ucl.ac.uk)

Online Supplementary file 2

Table E1. Number of responses to each question (see blank version of survey for questions, in Online Supplementary file 1).

Question	Total no. responses	Applies to Lay (L) / Professional (P)/ All (A)		Question	Total no. responses	Applies to Lay (L) / Professional (P)/ All (A)
1	941	A		25	251	L
2	369	L		26	289	L
3	336	L		27	286	L
4	302	L		28	267	L
5	351	L		29	279	L
6	348	L		30	261	L
7	327	L		31	289	P
8	343	L		32	172	P
9	333	L		33	172	P
10	345	L		34	164	P
11	318	L		35	136	P
12	317	L		36	167	P
13	252	L		37	164	P
14	248	L		38	157	P
15	243	L		39	151	P
16	190	L		40	165	P
17	319	L		41	165	P
18	121	L		42	442	A
19	296	L		43	228	A
20	292	L		44	445	A
21	276*	L		45	442	A
22	279*	L		46	439	A
23	284	L		47	314	A
24	289	L		48	36	A

*Responses to question 21 and 22 were used to generate the Spearman correlation coefficient for number of treatments and time taken for treatments. N=269 respondents answered both questions and therefore were included in this analysis.